Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2020

01-12-2020 | Glioma | Primary research

Engrailed 2 (EN2) acts as a glioma suppressor by inhibiting tumor proliferation/invasion and enhancing sensitivity to temozolomide

Authors: Tengfei Li, Wanchun Yang, Mao Li, Shuxin Zhang, Xingwang Zhou, Mingrong Zuo, Qiuyun Yuan, Mina Chen, Yanhui Liu

Published in: Cancer Cell International | Issue 1/2020

Login to get access

Abstract

Background

Glioma is one of the most malignant brain tumors and accounts for the majority of brain cancer related death. Despite progress on mechanistic studies, current understandings of the initiation and progression of glioma are still incomplete. Previous studies demonstrate that Engrailed-2 (EN2), a homeobox-containing transcription factor, is associated with tumorigenesis in a range of cancers heterogeneously, however, the profiles of EN2 expression and its potential functions in gliomas remain unclear.

Methods

Real-time PCR was used to identify the expression of EN2 in glioma tissues. To study the biological function of EN2 in glioma, we compared the cell viability and proliferation profiles between EN2 overexpressed and control cells using cell counting kit-8 (CCK8) assay, EdU incorporation assay and colony formation assay. Flow cytometry and Hoechst staining assays were performed to investigate the role of EN2 on glioma cell death. Finally, wound healing and transwell assays were carried out to investigate the role of EN2 on glioma cell invasion.

Results

We identified that EN2 was downregulated in human gliomas compared with paired adjacent normal tissues and negatively associated with glioma malignancy. Elevated EN2 expression inhibits cell proliferation, enhances glioma sensitivity to temozolomide and inhibits migration/invasion of glioma cells.

Conclusions

Our data identify a novel function of EN2 in glioma suppression and provide potential therapeutic targets for glioma therapy.
Literature
1.
Puchalski RB, Shah N, Miller J, Dalley R, Nomura SR, Yoon JG, Smith KA, Lankerovich M, Bertagnolli D, Bickley K, et al. An anatomic transcriptional atlas of human glioblastoma. Science (New York, NY). 2018;360(6389):660–3.CrossRef
2.
Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. JAMA. 2013;310(17):1842–50.CrossRef
3.
Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114(2):97–109.CrossRef
4.
Weller M, Wick W, Aldape K, Brada M, Berger M, Pfister SM, Nishikawa R, Rosenthal M, Wen PY, Stupp R, et al. Glioma. Nat Rev Dis Primers. 2015;1:15017.CrossRef
5.
Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459–66.CrossRef
6.
Hottinger AF, Stupp R, Homicsko K. Standards of care and novel approaches in the management of glioblastoma multiforme. Chin J Cancer. 2014;33(1):32–9.CrossRef
7.
Jhanwar-Uniyal M, Labagnara M, Friedman M, Kwasnicki A, Murali R. Glioblastoma: molecular pathways, stem cells and therapeutic targets. Cancers. 2015;7(2):538–55.CrossRef
8.
Lee SY. Temozolomide resistance in glioblastoma multiforme. Genes Dis. 2016;3(3):198–210.CrossRef
9.
Jornsten R, Abenius T, Kling T, Schmidt L, Johansson E, Nordling TE, Nordlander B, Sander C, Gennemark P, Funa K, et al. Network modeling of the transcriptional effects of copy number aberrations in glioblastoma. Mol Syst Biol. 2011;7:486.CrossRef
10.
Davidson EH. The regulatory genome: gene regulatory networks in development and evolution. Burlington: Academic; 2006. p. xi.
11.
Darnell JE. Transcription factors as targets for cancer therapy. Nat Rev Cancer. 2002;2(10):740–9.CrossRef
12.
Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH, et al. The somatic genomic landscape of glioblastoma. Cell. 2013;155(2):462–77.CrossRef
13.
Cancer Genome Atlas Research N. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455(7216):1061–8.CrossRef
14.
Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, et al. An integrated genomic analysis of human glioblastoma multiforme. Science (New York, NY). 2008;321(5897):1807–12.CrossRef
15.
Zhang X, Piano I, Messina A, D’Antongiovanni V, Cro F, Provenzano G, Bozzi Y, Gargini C, Casarosa S. Retinal defects in mice lacking the autism-associated gene Engrailed-2. Neuroscience. 2019;408:177–90.CrossRef
16.
Zunino G, Messina A, Sgado P, Baj G, Casarosa S, Bozzi Y. Brain-derived neurotrophic factor signaling is altered in the forebrain of Engrailed-2 knockout mice. Neuroscience. 2016;324:252–61.CrossRef
17.
Genestine M, Lin L, Durens M, Yan Y, Jiang Y, Prem S, Bailoor K, Kelly B, Sonsalla PK, Matteson PG, et al. Engrailed-2 (En2) deletion produces multiple neurodevelopmental defects in monoamine systems, forebrain structures and neurogenesis and behavior. Hum Mol Genet. 2015;24(20):5805–27.CrossRef
18.
Martin NL, Saba-El-Leil MK, Sadekova S, Meloche S, Sauvageau G. EN2 is a candidate oncogene in human breast cancer. Oncogene. 2005;24(46):6890–901.CrossRef
19.
Marszall MP, Sroka W, Adamowski M, Slupski P, Jarzemski P, Siodmiak J, Odrowaz-Sypniewska G. Engrailed-2 protein as a potential urinary prostate cancer biomarker: a comparison study before and after digital rectal examination. Eur J Cancer Prev. 2015;24(1):51–6.CrossRef
20.
Pandha H, Sorensen KD, Orntoft TF, Langley S, Hoyer S, Borre M, Morgan R. Urinary engrailed-2 (EN2) levels predict tumour volume in men undergoing radical prostatectomy for prostate cancer. BJU Int. 2012;110(6 Pt B):E287–92.CrossRef
21.
Chen JL, Li J, Kiriluk KJ, Rosen AM, Paner GP, Antic T, Lussier YA, Vander Griend DJ. Deregulation of a Hox protein regulatory network spanning prostate cancer initiation and progression. Clin Cancer Res. 2012;18(16):4291–302.CrossRef
22.
Javed S, Langley SE. Importance of HOX genes in normal prostate gland formation, prostate cancer development and its early detection. BJU Int. 2014;113(4):535–40.CrossRef
23.
Morgan R, Bryan RT, Javed S, Launchbury F, Zeegers MP, Cheng KK, James ND, Wallace DMA, Hurst CD, Ward DG, et al. Expression of Engrailed-2 (EN2) protein in bladder cancer and its potential utility as a urinary diagnostic biomarker. Eur J Cancer. 2013;49(9):2214–22.CrossRef
24.
Morgan R, Boxall A, Bhatt A, Bailey M, Hindley R, Langley S, Whitaker HC, Neal DE, Ismail M, Whitaker H, et al. Engrailed-2 (EN2): a tumor specific urinary biomarker for the early diagnosis of prostate cancer. Clin Cancer Res. 2011;17(5):1090–8.CrossRef
25.
Lin X, Liu X, Gong C. Expression of engrailed homeobox 2 regulates the proliferation, migration and invasion of non-small cell lung cancer cells. Oncol Lett. 2018;16(1):536–42.PubMedPubMedCentral
26.
McGrath SE, Annels N, Madhuri TK, Tailor A, Butler-Manuel SA, Morgan R, Pandha H, Michael A. Engrailed-2 (EN2)—a novel biomarker in epithelial ovarian cancer. BMC Cancer. 2018;18(1):943.CrossRef
27.
Lai CY, Xu Y, Yu GS, Wu X, Li YF, Pan B, Heng BL, Xue YJ, Su ZX. Engrailed-2 might play an anti-oncogenic role in clear-cell renal cell carcinoma. J Mol Histol. 2016;47(3):229–37.CrossRef
28.
Lai CY, Yu GS, Xu Y, Wu X, Heng BL, Xue YJ, Su ZX. Engrailed-2 promoter hyper-methylation is associated with its downregulation in clear cell renal cell carcinoma. Oncol Lett. 2017;14(6):6888–94.PubMedPubMedCentral
29.
Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28(1):27–30.CrossRef
30.
Greer PL, Greenberg ME. From synapse to nucleus: calcium-dependent gene transcription in the control of synapse development and function. Neuron. 2008;59(6):846–60.CrossRef
31.
McGrath SE, Michael A, Morgan R, Pandha H. EN2 in prostate cancer. Adv Clin Chem. 2015;71:47–76.CrossRef
32.
Killick E, Morgan R, Launchbury F, Bancroft E, Page E, Castro E, Kote-Jarai Z, Aprikian A, Blanco I, Clowes V, et al. Role of Engrailed-2 (EN2) as a prostate cancer detection biomarker in genetically high risk men. Sci Rep. 2013;3:2059.CrossRef
33.
Rosa MID, Dondossola ER, Alexandre MCM, Madeira K, Cardoso FA, Grande AJ. Urinary EN-2 to predict prostate cancer: systematic review and meta-analysis. Rev Assoc Med Bras (1992). 2017;63(7):656–61.CrossRef
34.
Lai CY, Pan B, Luo Y, Liang WB, Chen J, Ye DM, Guo JN, Li L, Su ZX. Engrailed-2 is down-regulated but also ectopically expressed in clear cell renal cell carcinoma. Mol Biol Rep. 2014;41(6):3651–7.CrossRef
35.
Guan R, Xu Y, Lei H, Gao Z, Xin Z, Guo Y. A novel protein is lower expressed in renal cell carcinoma. Int J Mol Sci. 2014;15(5):7398–408.CrossRef
36.
Shay G, Lynch CC, Fingleton B. Moving targets: emerging roles for MMPs in cancer progression and metastasis. Matrix Biol. 2015;44–46:200–6.CrossRef
37.
Rao JS, Yamamoto M, Mohaman S, Gokaslan ZL, Fuller GN, Stetler-Stevenson WG, Rao VH, Liotta LA, Nicolson GL, Sawaya RE. Expression and localization of 92 kDa type IV collagenase/gelatinase B (MMP-9) in human gliomas. Clin Exp Metas. 1996;14(1):12–8.CrossRef
Metadata
Title
Engrailed 2 (EN2) acts as a glioma suppressor by inhibiting tumor proliferation/invasion and enhancing sensitivity to temozolomide
Authors
Tengfei Li
Wanchun Yang
Mao Li
Shuxin Zhang
Xingwang Zhou
Mingrong Zuo
Qiuyun Yuan
Mina Chen
Yanhui Liu
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2020
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-020-1145-y

Other articles of this Issue 1/2020

Cancer Cell International 1/2020 Go to the issue

Primary research

Long noncoding RNA MIR99AHG promotes gastric cancer progression by inducing EMT and inhibiting apoptosis via miR577/FOXP1 axis

Primary research

Untargeted LC–MS/MS analysis reveals metabolomics feature of osteosarcoma stem cell response to methotrexate

Primary research

Evaluation of the upregulation and surface expression of hypoxanthine guanine phosphoribosyltransferase in acute lymphoblastic leukemia and Burkitt’s B cell lymphoma

Primary research

CircHIPK3 promotes proliferation and metastasis and inhibits apoptosis of renal cancer cells by inhibiting MiR-485-3p

Review

Early diagnosis of breast and ovarian cancers by body fluids circulating tumor-derived exosomes

Primary research

High CENPM mRNA expression and its prognostic significance in hepatocellular carcinoma: a study based on data mining
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits